Sanofi Reports Results of Dupixent (dupilumab) in P-III LIBERTY ASTHMA VOYAGE Study in Children with Asthma

Shots:

• The P-III LIBERTY ASTHMA VOYAGE study involves assessing of Dupixent (SC, 100/200mg, q2w ) + SOC maintenance therapy of medium-dose ICS with a second controller medication/ high-dose ICS with/out second controller medication vs PBO in 408 children 6 to <12 years old with uncontrolled moderate-severe asthma
• Results: Patients with baseline blood EOS ≥300 cells/μl and patients with markers of type 2 inflammation (FeNO ≥20 ppb or EOS ≥150 cells/μl), reduction in the rate of asthma attacks, with 65% & 59% average reduction over 1yr. (0.24 and 0.31 vs 0.67 and 0.75 events/year), improvement in lung function @12wks. (10.15 and 10.53 vs 4.83 and 5.32); improvement in lung function was observed as early as 2wks.and was sustained for up to 52wks. respectively
• Dupixent is a mAb that inhibits the signaling of the IL-4 & IL-13 proteins with its expected regulatory submissions in the US & EU for children aged 6-11 yrs. in Q1’21
  
  Click here ­to­ read full press release/ article | Ref: GlobeNewswire | Image: BioPharma Reporter